Explaining the decrease in mortality from abdominal aortic aneurysm rupture
A Anjum, R von Allmen, R Greenhalgh, J T Powell, A Anjum, R von Allmen, R Greenhalgh, J T Powell
Abstract
Background: A steady rise in mortality from abdominal aortic aneurysm (AAA) was reported in the 1980s and 1990 s, although this is now declining rapidly. Reasons for the recent decline in mortality from AAA rupture are investigated here.
Methods: Routine statistics for mortality, hospital admissions and procedures in England and Wales were investigated. All data were age-standardized. Trends in smoking, hypertension and treatment for hypercholesterolaemia (statins), together with regression coefficients for mortality, were available from public sources for those aged at least 65 years. Deaths from ruptured AAA avoided in this age group were estimated by using the IMPACT equation: deaths avoided = (deaths in index year) × (risk factor decline) × β-coefficient.
Results: From 1997, deaths from ruptured AAA have decreased sharply, almost twofold in men. Hospital admissions for elective AAA repair have increased modestly (from 40 to 45 per 100,000 population), attributable entirely to more procedures in those aged 75 years and over (P < 0.001). Admissions for ruptured AAA have declined from 18.6 to 13.5 per 100,000 population, across all ages, with the proportion offered and surviving emergency repair unchanged. From 1997, mortality from ruptured aneurysm in those aged at least 65 years has fallen from 65.9 to 44.6 per 100,000 population. An estimated 8-11 deaths per 100,000 population were avoided by a reduced prevalence of smoking and a similar number from an increase in the number of elective AAA repairs. Estimates for the effects of blood pressure and lipid control are uncertain.
Conclusion: The reduction in incidence of ruptured AAA since 1997 is attributable largely to changes in smoking prevalence and increases in elective AAA repair in those aged 75 years and over.
Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Source: PubMed
다가오는 임상 시험
-
Magnus MedicalCongressionally Directed Medical Research Programs모병
-
Nicholas ButowskiSiren Biotechnology아직 모집하지 않음신경교종 | 뇌종양 | 재발성 고등급 신경교종미국
-
State University of New York at Buffalo아직 모집하지 않음
-
Poitiers University Hospital아직 모집하지 않음
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음
-
University of California, Irvine모병뇌암 | CNS 암 | 신경계 암 | 뇌전이암미국
-
Guangdong Raynovent Biotech Co., Ltd아직 모집하지 않음
-
The Hong Kong Polytechnic UniversityWu Jieh Yee Charitable Foundation모병
-
Shanghai General Hospital, Shanghai Jiao Tong University...아직 모집하지 않음
-
Sun Yat-sen University아직 모집하지 않음금연 | AI 에이전트 | Early-Stage Cancer
-
Affiliated Hospital of Nantong University아직 모집하지 않음